<a href="https://www.fiercebiotech.com/biotech/asco-cardiff-posts-updated-colorectal-cancer-data-ahead-pivotal-push" hreflang="en">ASCO: Cardiff posts updated colorectal cancer data ahead of pivotal push</a>
Cardiff Oncology presented updated results from its phase 2 trial of onvansertib for RAS-mutated metastatic colorectal cancer at the ASCO 2026 meeting, highlighting a 72.2% response rate with the drug combined with FOLFIRI/bev, although it has not yet reached median progression-free survival (PFS). The company plans to advance the 30 mg dose into phase 3 trials, despite concerns about its limited efficacy with other chemotherapy regimens and potential adoption challenges.
For a professional tracking healthtech and biotech developments, the key insight from Cardiff Oncology's latest data is their strategic decision to advance the 30 mg dose of onvansertib in combination with FOLFIRI/bev into phase 3 trials due to its promising progression-free survival results. However, the lack of efficacy with the FOLFOX/bev combination suggests potential market limitations, highlighting a need for careful consideration of commercial and regulatory strategies, as well as potential partnerships or funding rounds to support the pivotal study.